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Edited by Miguel De la RosaAbstract Endostatin has a compact structure with a Zn(II)-
binding site (His1, His3, His11, and Asp76) at the N-terminus.
In this study, the eﬀects of Zn(II)-binding on the folding and sta-
bility of recombinant human endostatin were studied. The results
show that Zn(II)-binding largely stabilizes the structure of endo-
statin at physiological pH. Under some proteolytic conditions,
Zn(II)-binding also contributes to the integrity of the N-terminus
of endostatin, which is critical for endostatin to maintain a stable
structure. Moreover, engineering an extra Zn(II)-binding peptide
to the N-terminus of human endostatin makes this molecule more
stable and cooperative in the presence of Zn(II).
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Endostatin (ES), a 20 kDa C-terminal fragment of collagen
XVIII, was discovered for its potent inhibitory function on
angiogenesis and tumor growth without toxicity and acquired
drug resistance [1–3]. X-ray crystallography of ES shows a
compact structure composed of predominant b-sheets and
loops, two pairs of disulﬁde bonds, and a Zn(II)-binding site
at the N-terminus [4,5]. His1, His3, His11, and Asp76 coordi-
nate with Zn(II) in human ES, and these four ligands are also
conserved in murine and dog ES [4–6].
Among the four Zn(II)-binding ligands, His1, His3, and
Asp76 are critical for Zn(II)-binding in ES [4,6]. The double
mutant H1/3A, which cannot bind Zn(II), abolishes ES antitu-
mor activity completely in the Lewis lung carcinoma model [7].
Site mutation in His11 or Asp76 also signiﬁcantly reduces the
antitumor activity of full length ES [7]. Recently, Javaherian
and his colleagues reported that Zn(II)-binding is required
for antitumor and antimigration activities of an N-terminalAbbreviations: ES, endostatin; FZ, FluoZin-1, tripotassium salt; CD,
circular dichroism; FPLC, fast protein liquid chromatography;
GdmC1, guanidine hydrochloride; DSC, diﬀerential scanning calo-
rimetry; ZBP, Zn(II)-binding peptide; ZBP-ES, Zn(II)-binding peptide
modiﬁed endostatin
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doi:10.1016/j.febslet.2007.05.05827-amino-acid peptide of ES [8]. However, controversial re-
ports on the role of Zn(II) in the biological activity of ES show
that N-terminal deleted mutant of human ES act as eﬃciently
as the wild-type ES [9–11]. In order to further explain these
inconsistent results, more studies on the eﬀects of Zn(II)-bind-
ing on ES are needed.
On the other hand, it was proposed that Zn(II) is likely to
play a structural role in ES [5]. Zn(II)-dependent dimer was
observed in the crystal instead of in the solution of human
ES [4]. Surface plasmon resonance analysis shows that the
binding of ES to heparin and heparan sulfate requires the pres-
ence of Zn(II) [12]. As an important constituent of ES, the con-
tribution of Zn(II) to the folding behavior and the overall
stability of ES has not been reported yet, nor the binding aﬃn-
ity between ES and Zn(II).
In this study, the eﬀects of Zn(II)-binding on the folding and
stability of recombinant human ES were studied using ther-
mal- and guanidine hydrochloride (GdmC1)-induced unfold-
ing monitored by diﬀerential scanning calorimetry (DSC)
and tryptophan emission ﬂuorescence, respectively. Our results
show that upon Zn(II)-binding, ES is more stable against heat,
denaturant, and certain proteolytic conditions. Moreover,
engineering a Zn(II)-binding peptide (ZBP) to the N-terminus
of ES enhances the Zn(II)-binding capacity, which endows
holo ZBP-ES a more stable and cooperative structure than
holo ES. These observations provide a structural basis for fur-
ther understanding the molecular behavior involved in the bio-
physical and biological functions of ES and Zn(II).2. Materials and methods
2.1. Preparation of ES and its variants
Both ES and ZBP-ES expressed by Escherichia coli were provided by
Protgen Ltd. Fragment-179 was puriﬁed directly from the trypsin
digested products of apo ES. Apo ES (0.5 mg/ml) was digested by
25 U/ml trypsin at 37 C in 10 mM Tris, pH 7.4, for 20 min, then the
products were applied on a SP Sepharose High Performance (Amer-
sham) column equilibrated in 10 mM Tris–HCl, pH 8.0, and eluted
by linear gradient of NaCl concentration. Protein concentrations were
determined by BCA protein assay reagent kit (Pierce).
2.2. Apo and holo sample preparation and Zn(II) content analysis
To prepare the apo and holo samples, 100-fold molar excess EDTA
or ZnCl2 was incubated with protein sample in 5 mM Tris–HCl, pH
7.4, at room temperature overnight and then extensively dialyzed to
5 mM Tris–HCl, pH 7.4. The Zn(II) content was measured by atomic
emission spectroscopy with an OPTIMA 3300RL instrument.
2.3. Determination of Zn(II)-binding aﬃnity
The dissociation constants for Zn(II)-binding in ES and ZBP-ES
were obtained from competition titration as described in Refs.blished by Elsevier B.V. All rights reserved.
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(FZ) (tripotassium salt) was used. FZ can form a 1:1 complex with
Zn(II) speciﬁcally, with dramatic ﬂuorescence intensity increase at
516 nm when excited at 495 nm [15]. FZ (0.125 lM) alone was titrated
with Zn(II) to obtain the dissociation constant (K0) of the FZ–Zn(II)
complex. For determining the Zn(II)-binding aﬃnity to ES or ZBP-
ES, the mixture of FZ (0.125 lM) and ES or ZBP-ES (0.5 lM) was ti-
trated with Zn(II). All of the experiments were carried out in 10 mM
Tris–HCl, pH 7.4, at 20 C. The following equilibria were used for cal-
culation:
½FZZnðIIÞ
½FZtotal
¼ F  F 0
F maxF 0 ð1Þ
FZZnðIIÞ$K0 FZþZnðIIÞ K0 ¼ ½FZ½ZnðIIÞ½FZZnðIIÞ ð2Þ
ESZnðIIÞ$K1 ESþZnðIIÞ K1 ¼ ½ES½ZnðIIÞ½ESZnðIIÞ ð3Þ
ESZnðIIÞ2$
K2
ESZnðIIÞþZnðIIÞ K2 ¼ ½ESZnðIIÞ½ZnðIIÞ½ESZnðIIÞ2
ð4Þ
where F denotes ﬂuorescence intensity measured at the wavelength of
516 nm, F0 is the ﬂuorescence background of FZ, Fmax is the maximal
ﬂuorescence intensity, K1 and K2 are the dissociation constants for the
ﬁrst and the second Zn(II) ion binding in protein, respectively. For
protein which has only one Zn(II)-binding site, Eqs. (1)–(3) are used,
while for protein which has two binding sites, Eqs. (1)–(4) are used.
In this study K0 = 7.87 lM was obtained, slightly deviating from the
K0 (8 lM) provided by manufacturer. Based on Zn(II) content and
binding aﬃnities of holo ES and ZBP-ES, extra Zn(II) (10-fold molar
excess of protein) was added into the holo samples in the following
experiments to make sure that holo ES and ZBP-ES were predomi-
nantly in the bound forms at neutral pH (>90%, according to the dis-
sociation constants). Higher Zn(II) concentration was avoided taking
account of the probability of cation or anion eﬀect brought by ZnCl2
in the unfolding studies.
2.4. Fluorescence measurements
Fluorescence measurements were carried out using an F-4500 ﬂuo-
rescence spectrophotometer (Hitachi) with a cuvette of 1 cm light path.
The slit widths for excitation and emission were 5 and 10 nm, respec-
tively. The scan speed was 240 nm/min [16–19].
2.5. GdmCl-induced unfolding
The concentration of ES or its variants was 0.8 lM in 5 mM Tris–
HCl, pH 7.4, which contains diﬀerent GdmCl concentrations ranging
from 0 to 6 M. After incubation for over 120 min, ﬂuorescence mea-
surements were carried out. All of the measurements were repeated
for three times and data were analyzed according to the procedure
of Santoro and Bolen [20].
2.6. Circular dichroism (CD) spectroscopy
The far- and near-UV CD spectra were obtained using a Jasco-715
spectropolarimeter. The concentration of protein was 10 lM, in 5 mM
Tris–HCl, pH 7.4. The spectra were measured in 0.1 (far-UV) and 1 cm
(near-UV) quartz cuvette. An average of three scans was recorded
and corrected by subtracting the baseline spectrum of the buﬀer. The
CD signal was converted to molar ellipticity per residue [h]
(deg cm2 dmol1). All measurements were carried out at 20 C.
2.7. Diﬀerential scanning calorimetry (DSC)
DSC thermograms were recorded in a micro DSC III (Setaram,
France). Each sample was in 10 mM HEPES buﬀer at pH 7.0 with a
ﬁnal ES concentration of 2.86 mg/ml. The heating rate is 0.5 C/min.
A reference blank containing all reagents except ES was measured
for each sample at identical settings. Data were analyzed as described
by Brandts and his colleagues [21].
2.8. Proteolysis assay
EDTA or ZnCl2 (1 mM) was pre-incubated with ES (0.2 mg/ml) for
10 min at 37 C before trypsin (62.5 U/ml) was added. At each time
point, reaction solution was quickly taken out and mixed with reduced
SDS–PAGE loading buﬀer to stop the proteolysis reactions. All of the
experiments were carried out in PBS buﬀer, pH 7.4, at 37 C.2.9. Mass spectrometry
The largest fragment of trypsin-digested apo ZBP-ES were separated
by SDS-PAGE, and then analyzed by matrix-assisted laser desorption/
ionization time of ﬂight (MALDI-TOF) mass spectrometry using a
Bruker Biﬂex linear time-of-ﬂight spectrometer (Bruker Franzen, Bre-
men, Germany). The MALDI-TOF data were searched in the Swiss-
Prot protein data base for protein identiﬁcation.3. Results
3.1. Structure analyses and Zn(II)-binding aﬃnity measurement
As described in our previous studies, tryptophan emission
ﬂuorescence is a good probe for detecting the tertiary structure
changes of ES [16–19]. Fig. 1A shows a 3D structure model of
ES, in which the Zn(II)-binding site and the four tryptophan
residues are indicated [4]. Apo and holo ES show very similar
tryptophan ﬂuorescence spectra at neutral pH (Fig. 1B), which
may imply that Zn(II)-binding has little eﬀect on the environ-
ment in which the four tryptophan residues are located. The
tertiary and secondary structure of apo and holo ES do not
change much, as evidenced by the near- and far-UV CD spec-
tra, respectively (Fig. 1C and D). These results show that
Zn(II)-binding does not bring evident changes to the overall
structure of ES. In our experiment, the dimer formation of
holo ES was not detected in solution at physiological pH by
Fast protein liquid chromatography (FPLC) size-exclusion
chromatography (data not shown).
Atomic emission spectroscopy results show that holo ES
contains about one Zn(II) ion per molecule (Zn(II)/ES is
0.9), which is consistent with previous reports [4,6]. The aﬃnity
of ES for Zn(II) was determined by competition titration with
a Zn(II) ﬂuorescence indicator, FluoZin-1 (FZ). Fig. 2 shows
the plots of ﬂuorescence intensity at 516 nm as a function of
total added Zn2+. Data of ES were best ﬁtted to Eq. (1)–(3),
which describes a single binding site for Zn2+, and the dissoci-
ation constant of ES–Zn(II) complex is 6.7 nM.
3.2. Calorimetric study of ES by DSC
The thermograms showing the excess heat capacity (Cp) as a
function of temperature are shown in Fig. 3. The transition
temperatures (Tm) of apo ES is 52.1 C. Zn(II)-binding shifts
the transition peak towards higher temperature, with a
9.1 C increase in DTm. These results demonstrate that
Zn(II)-binding stabilizes holo ES against heat.
3.3. Limited protease digestion
Trypsin is a commonly used protease, which cleaves
C-terminal peptide bonds of the Arg and Lys residues. Since
all of the 15 Arg and 5 Lys residues in ES are on the surface
of the tertiary structure of the molecule [4], trypsin was used
as a tool to probe possible conformational change of ES upon
Zn(II)-binding. When digested under the same condition, apo
ES was quickly digested within 10 min, while intact holo ES
could not be totally digested even after 6 h (Fig. 4).
In addition, diﬀerent digestion manners were observed with
apo and holo ES. Apo ES experienced a two-stage digestion
process, during which a dominant fragment was obtained
within 3 min and was further degraded. In contrast, intact holo
ES follows a continuous digestion process (Fig. 4). These re-
sults indicate that Zn(II)-binding may protect certain suscepti-
ble cleavage sites of ES thus stabilizing ES against trypsin.
Peptide mass ﬁngerprinting shows that only the ﬁrst four ami-
Fig. 2. Zn(II)-binding aﬃnity measurement. Plots of ﬂuorescence
intensity at 516 nm as a function of total Zn(II) in the competition
experiments using FluoZin-1 to determine the Zn(II)-binding aﬃnity
of ES. Solid lines show the ﬁtted data.
Fig. 3. DSC thermograms of apo and holo ES. All of the scans were
carried out in 10 mM HEPES buﬀer, pH 7.0, with a heating rate of
0.5 C/min.
Fig. 1. Tertiary and secondary structure analyses of apo and holo ES. (A) Crystal structure diagram of ES (NCBI Chemical Data, edited by Cn3D
program) [4]. (B) Fluorescence spectra excited at 288 nm. (C) Near-UV CD spectra. (D) Far-UV CD spectra. All measurements were carried out at
20 C, and 10-fold molar excess EDTA or ZnCl2 was added to apo and holo ES samples, respectively.
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residues from the Zn(II)-binding site, of the apo ES were lost
in this main fragment. Since the N-terminal loop of ES was re-
ported to stretch out of the core structure [4], it is reasonable to
conclude that the subtle conformational change of the N-ter-
minal loop of ES upon Zn(II)-binding may not induce an evi-
dent change to the overall structure of ES (Fig. 1B–D).
3.4. GdmCl-induced unfolding of ES
GdmCl-induced unfolding of apo and holo ES was moni-
tored by the tryptophan emission ﬂuorescence at 20 C
(Fig. 5A and B). The unfolding curves of holo ES has dramatic
shifts towards higher GdmCl concentrations compared withapo ES, with increases in both DGN-U and Cm (Table 1). How-
ever, Zn(II)-binding causes a decrease of the m* value. These
results show that Zn(II)-binding largely stabilizes the structure
of ES, while decreases its unfolding cooperativity.
HSHR-deﬁcient fragment of apo ES (fragment-179) was
puriﬁed from trypsin-digested products of apo ES for further
study. Removal of the ﬁrst four amino acid residues results
in the loss of Zn(II) -binding to ES [4]. At pH 7.4, although
fragment-179 shows a similar ﬂuorescence proﬁle as wild-type
apo and holo ES (data not shown) in the absence of Zn(II), it is
less stable than either apo or holo ES in GdmCl-induced
Fig. 4. Trypsin digestion proﬁle of apo and holo ES in PBS buﬀer, pH
7.4, at 37 C.
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formed (Fig. 5C). The unfolding cooperativity of fragment-
179 is signiﬁcantly higher than that of either apo or holo ES
reﬂected by a higher m* (Table 1). The decreased stability to-
gether with the largely increased unfolding cooperativity im-
plies a very fragile structure of fragment-179. In addition,
the Cm of apo ES against GdmCl decreased 0.48 M when the
temperature increased from 20 C to 37 C, while the Cm of
holo ES only decreases 0.06 M (Table 1). These results show
that holo ES is less sensitive to the change of temperature than
apo ES during the GdmCl-induced unfolding process.
3.5. Engineering Zn(II)-binding peptide improves the
biophysical properties of ES
Pharmacokinetics studies show that engineering a peptide
with the sequence of MGGSHHHHH at the N-terminus of
human ES endows ES a much longer half life at equal doseFig. 5. GdmCl-induced unfolding of ES monitored by the tryptophan emissio
using relative ﬂuorescence intensity monitored at 318 nm at 20 C. (B) Norm
ES and puriﬁed fragment-179 at 37 C.in animal models [22,23]. Since this engineered sequence con-
tains ﬁve His residues in a row, which might serve as a
Zn(II)-binding peptide (ZBP), it is reasonable to hypothesize
that this ZBP upon binding to Zn(II) may contribute to the im-
proved pharmacokinetics properties. Indeed, ZBP-ES was
measured to bind one more Zn(II) ion than ES in solution in
our study. Using two Zn(II)-binding sites model in the compe-
tition titration, the ﬁrst (K1) and the second (K2) dissociation
constant for ZBP-ES were measured to be 9 nM and
44.7 nM, respectively. Taking account of the K1 of ES, the
K1 of ZBP-ES may be responsible for the intrinsic Zn(II)-bind-
ing site (composed by His1, His3, His11, and Asp76), and K2 is
for ZBP.
GdmCl-induced unfolding of ZBP-ES shows that Zn(II)-
binding also largely stabilizes ZBP-ES (Fig. 6). From the
parameters listed in Table 1, upon Zn(II)-binding, the
DGN-U, m
*, and Cm of holo ZBP-ES increase more dramati-
cally than those of holo ES, which results higher stability
and cooperativity of holo ZBP-ES than holo ES. ES mutant
D76A was reported to have no Zn(II)-binding ability [6]. To
exclude the possible structural role of the ZBP itself, we used
mutant ZBP-ES-D76A to study the GdmCl-induced unfold-
ing. Results show that holo ZBP-ES-D76A can bind one
Zn(II), however, Zn(II)-binding cannot stabilize holo ZBP-
ES-D76A (Table 1). These results demonstrate that the two
Zn(II) ions in ZBP-ES have a synergetic eﬀect on the structural
stability and unfolding cooperativity of ZBP-ES. It is also
quite possible that in ZBP-ES or ZBP-ES-D76A the coordina-
tion pattern is rearranged using the possible Zn(II) ligands
such as Asp5 which was found to be another Zn(II)-binding li-
gand in murine ES under certain conditions [6].n ﬂuorescence. (A) Raw data and ﬁtted data of unfolding process of ES
alized data of A. (C) Normalized data of GdmCl-induced unfolding of
Table 1
Parameters of GdmCl-induced unfolding
DGN-U
a
(kJ mol1)
m*b
(kJ mol1 M1)
Cm
c
(M)
Apo ES, 20 C 30.47 14.58 2.09
Holo ES, 20 C 33.89 13.24 2.56
Apo ES, 37 C 18.58 11.54 1.61
Holo ES, 37 C 23.95 9.58 2.50
Fragment-179, 37 C 19.37 16.99 1.14
Apo ZBP-ES, 20 C 24.84 12.06 2.06
Holo ZBP-ES, 20 C 40.84 15.47 2.64
Apo ZBP-ES-D76A, 20 C 21.41 11.96 1.79
Holo ZBP-ES-D76A, 20 C 11.78 6.58 1.79
aDG0N-U, the free energy change in the absence of denaturant.
bm*, the apparent m value deﬁned by the linear extrapolation model.
cCm, the concentration of GdmCl at the midpoint of the unfolding
transition.
Fig. 6. GdmCl-induced unfolding of apo and holo ZBP-ES. The
symbols are normalized data. All of the measurements were carried out
at 20 C.
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Our group previously reported that ES is acid-resistant, and
its two pairs of disulﬁde bonds contribute signiﬁcantly to the
structural stability and the biological activity of ES [16–19].
Here, we show that Zn(II) is another important factor to the
stability of ES, which provides clues to the refolding, prepara-
tion, and preservation of ES. It is also very necessary to distin-
guish the apo and holo forms in future studies on biophysical
and biochemical properties of ES. These results also provide
insight into the function of Zn(II) on ES activity, which may
partly take eﬀect through stabilizing the N-terminus of ES,
and thus stabilize the entire tertiary structure.
Holo ES, which is speculated to be dominant in vivo [4],
shows higher stability than apo ES. It is reasonable to hypoth-
esize that Zn(II)-binding enables holo ES to be more resistant
under stressed conditions and retain a higher stability in circu-
lation than apo ES. Fragment-179 is one species existing in the
recombinant human ES products expressed by Pichia pastoris
[22]. Our studies on the decreased stability of fragment-179
may provide an explanation for the short half lives of ES
in some pharmacokinetics studies, in which ES expressed by
P. pastoris was used [22].
It has been reported that ZBP-ES has an anti-tumor activity
with high clinical beneﬁt rate and is well tolerated in pre-
treated advanced non-small cell lung cancer patients [24,25].Compared with ES, the therapeutic doses of ZBP-ES are lower
and the half lives at equal doses are longer in both animal tests
and clinical studies [22–27]. These observations may imply the
higher eﬃcacy and stability of ZBP-ES in vivo. Parallel studies
show that ZBP-ES has more potent anti-angiogenic activities
in vitro and anti-tumor activities in vivo compared with ES
(to be submitted). From our studies on the structural roles
of Zn(II)-binding in ES and ZBP-ES, a plausible explanation
of the above phenomena is that the stable structure of holo
ZBP-ES lowers its clearance rate from the body.Acknowledgement: This work was supported by grants from the Major
Program of National Science Foundation of China (No. 30291000).
We gratefully acknowledge members of the Luo laboratory for insight-
ful discussions and criticism throughout the course of this work.References
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